Pharvaris NV

詳細情報 Pharvaris NV 企業名

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

企業情報

企業コードPHVS

会社名Pharvaris NV

上場日Feb 05, 2021

最高経営責任者「CEO」Mr. Berndt Modig, CPA

従業員数- -

証券種類Ordinary Share

決算期末Feb 05

本社所在地Emmy Noetherweg 2

都市LEIDEN

証券取引所NASDAQ Global Select Consolidated

国Netherlands

郵便番号2333 BK

電話番号31712036410

ウェブサイトhttps://pharvaris.com/

企業コードPHVS

上場日Feb 05, 2021

最高経営責任者「CEO」Mr. Berndt Modig, CPA

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. David P. Meeker ,M.D.

Non-Executive Director

102.82K

-15.53%

Ms. Viviane Monges

Non-Executive Director

54.91K

+73.10%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+0.63%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+128.70%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

--

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

--

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

--

Dr. Anne Marie De Jonge Schuermans, Ph.D.

Non-Executive Director

--

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

--

Dr. Morgan Conn, Ph.D.

Chief Business Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. David P. Meeker ,M.D.

Non-Executive Director

102.82K

-15.53%

Ms. Viviane Monges

Non-Executive Director

54.91K

+73.10%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+0.63%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+128.70%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

--

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Tue, Aug 19

株主統計

種類

株主統計

比率

General Atlantic LLC

11.76%

Fidelity Management & Research Company LLC

8.47%

Foresite Capital Management, LLC

6.89%

VenBio Partners LLC

6.70%

Viking Global Investors LP

5.70%

他の

60.49%

株主統計

比率

General Atlantic LLC

11.76%

Fidelity Management & Research Company LLC

8.47%

Foresite Capital Management, LLC

6.89%

VenBio Partners LLC

6.70%

Viking Global Investors LP

5.70%

他の

60.49%

種類

株主統計

比率

Private Equity

25.72%

Investment Advisor

16.37%

Hedge Fund

14.25%

Venture Capital

13.60%

Investment Advisor/Hedge Fund

6.26%

Individual Investor

5.32%

Research Firm

0.08%

Bank and Trust

0.04%

Pension Fund

0.03%

他の

18.34%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

125

52.21M

81.51%

-1.38M

2025Q1

125

53.89M

99.06%

+200.61K

2024Q4

123

53.45M

98.98%

+218.03K

2024Q3

114

53.86M

99.73%

+1.03M

2024Q2

83

52.08M

96.43%

-141.66K

2024Q1

76

49.63M

98.30%

-831.88K

2023Q4

69

47.76M

94.74%

+8.60M

2023Q3

54

36.05M

91.51%

-2.92M

2023Q2

53

35.78M

91.11%

+3.65M

2023Q1

61

28.67M

84.75%

-3.62M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

General Atlantic LLC

7.53M

13.82%

--

Mar 31, 2025

Fidelity Management & Research Company LLC

5.40M

9.9%

--

Mar 31, 2025

Foresite Capital Management, LLC

4.41M

8.09%

+12.70K

+0.29%

Mar 31, 2025

VenBio Partners LLC

4.29M

7.87%

--

Mar 31, 2025

Viking Global Investors LP

3.65M

6.7%

--

Mar 31, 2025

EQT Life Sciences

3.56M

6.53%

--

Apr 01, 2025

Bain Capital Life Sciences Investors, LLC

3.30M

6.06%

--

Mar 31, 2025

VR Adviser, LLC

3.11M

5.71%

-107.41K

-3.34%

Mar 31, 2025

Deerfield Management Company, L.P.

2.02M

3.7%

--

Mar 31, 2025

Commodore Capital LP

1.91M

3.51%

--

Mar 31, 2025

詳細を見る

23.560USD

Pharvaris NV

23.560

概要

企業名

金融

分析